Belinda H McCully1, Charlie E Wade, Erin E Fox, Kenji Inaba, Mitchell J Cohen, John B Holcomb, Martin A Schreiber. 1. From the Division of Trauma, Critical Care & Acute Care Surgery, Department of Surgery (B.H.M., M.A.S.), Oregon Health & Science University, Portland, Oregon; Center for Translational Injury Research, Division of Acute Care Surgery, Department of Surgery (C.E.W., E.E.F.), University of Texas Health Science Center, Houston, Texas; Division of Acute Care Surgery, Department of Surgery (K.I.), University of Southern California, Los Angeles, California; Department of Surgery (M.J.C.), Denver Health Medical Center and the University of Colorado; Denver, Colorado; and Department of Surgery (J.B.H.), University of Alabama at Birmingham, Birmingham, Alabama.
Abstract
BACKGROUND: The Pragmatic Randomized Optimal Platelet and Plasma Ratios (PROPPR) trial showed that 15% of patients developed venous thromboembolism (VTE) following hemorrhage, but the mechanisms are unknown. Since inflammation is associated with hypercoagulability and thrombosis, our goal was to compare the temporal inflammatory profile following hemorrhagic shock in patients with and without VTE. STUDY DESIGN: Secondary analysis was performed on data collected from PROPPR. Blood samples collected at 0 hour, 2 hours, 4 hours, 6 hours, 12 hours, 24 hours, 48 hours, and 72 hours following admission were assayed on a 27-target cytokine panel, and compared between VTE (n = 83) and non-VTE (n = 475) patients. p < 0.05 indicated significance. RESULTS: Over time, both groups exhibited elevations in proinflammatory mediators interleukin (IL)-6, IL-8, IL-10, granulocyte colony-stimulating factor 57, monocyte chemoattractant protein 1 and macrophage inflammatory protein 1β, and anti-inflammatory mediators IL-1ra and IL-10 (p < 0.05 vs. admission). Venous thromboembolism patients showed amplified responses for IL-6 (6-72 hours) and IL-8 (6-24 hours), which peaked at later time points, and granulocyte colony-stimulating factor 57 (12-24 hours), monocyte chemoattractant protein 1 (6-72 hours), and macrophage inflammatory protein-1 β (2-12 hours) (p < 0.05 vs. non-VTE per time point) that peaked at similar time points to non-VTE patients. The anti-inflammatory responses were similar between groups, but the interleukin-mediated proinflammatory responses continued to rise after the peak anti-inflammatory response in the VTE group. The occurrence rate of adverse events was higher in VTE (97%) versus non-VTE (87%, p = 0.009) and was associated with higher inflammation. CONCLUSION: Patients with VTE following hemorrhagic shock exhibited a prolonged and amplified proinflammatory responses mediated by select interleukin, chemotactic, and glycoprotein cytokines that are not antagonized by anti-inflammatory mediators. This response is not related to randomization group, injury severity or degree of shock, but may be linked to adverse events. LEVEL OF EVIDENCE: Prognostic, level III.
BACKGROUND: The Pragmatic Randomized Optimal Platelet and Plasma Ratios (PROPPR) trial showed that 15% of patients developed venous thromboembolism (VTE) following hemorrhage, but the mechanisms are unknown. Since inflammation is associated with hypercoagulability and thrombosis, our goal was to compare the temporal inflammatory profile following hemorrhagic shock in patients with and without VTE. STUDY DESIGN: Secondary analysis was performed on data collected from PROPPR. Blood samples collected at 0 hour, 2 hours, 4 hours, 6 hours, 12 hours, 24 hours, 48 hours, and 72 hours following admission were assayed on a 27-target cytokine panel, and compared between VTE (n = 83) and non-VTE (n = 475) patients. p < 0.05 indicated significance. RESULTS: Over time, both groups exhibited elevations in proinflammatory mediators interleukin (IL)-6, IL-8, IL-10, granulocyte colony-stimulating factor 57, monocyte chemoattractant protein 1 and macrophage inflammatory protein 1β, and anti-inflammatory mediators IL-1ra and IL-10 (p < 0.05 vs. admission). Venous thromboembolism patients showed amplified responses for IL-6 (6-72 hours) and IL-8 (6-24 hours), which peaked at later time points, and granulocyte colony-stimulating factor 57 (12-24 hours), monocyte chemoattractant protein 1 (6-72 hours), and macrophage inflammatory protein-1 β (2-12 hours) (p < 0.05 vs. non-VTE per time point) that peaked at similar time points to non-VTE patients. The anti-inflammatory responses were similar between groups, but the interleukin-mediated proinflammatory responses continued to rise after the peak anti-inflammatory response in the VTE group. The occurrence rate of adverse events was higher in VTE (97%) versus non-VTE (87%, p = 0.009) and was associated with higher inflammation. CONCLUSION: Patients with VTE following hemorrhagic shock exhibited a prolonged and amplified proinflammatory responses mediated by select interleukin, chemotactic, and glycoprotein cytokines that are not antagonized by anti-inflammatory mediators. This response is not related to randomization group, injury severity or degree of shock, but may be linked to adverse events. LEVEL OF EVIDENCE: Prognostic, level III.
Authors: Sean P McCully; Tim H Lee; Belinda H McCully; Claire L Sands; Elizabeth A Rick; Rondi K Dean; Nathan W Anderson; David A Hampton; Scott G Louis; Jerome A Differding; Martin A Schreiber Journal: J Trauma Acute Care Surg Date: 2015-02 Impact factor: 3.313
Authors: Jeffrey N Harr; Ernest E Moore; Theresa L Chin; Arsen Ghasabyan; Eduardo Gonzalez; Max V Wohlauer; Angela Sauaia; Anirban Banerjee; Christopher C Silliman Journal: Shock Date: 2014-01 Impact factor: 3.454
Authors: Sarah Baraniuk; Barbara C Tilley; Deborah J del Junco; Erin E Fox; Gerald van Belle; Charles E Wade; Jeanette M Podbielski; Angela M Beeler; John R Hess; Eileen M Bulger; Martin A Schreiber; Kenji Inaba; Timothy C Fabian; Jeffrey D Kerby; Mitchell Jay Cohen; Christopher N Miller; Sandro Rizoli; Thomas M Scalea; Terence O'Keeffe; Karen J Brasel; Bryan A Cotton; Peter Muskat; John B Holcomb Journal: Injury Date: 2014-06-10 Impact factor: 2.586
Authors: Ioannis N Liras; Elaheh Rahbar; Matthew T Harting; John B Holcomb; Bryan A Cotton Journal: J Trauma Acute Care Surg Date: 2016-05 Impact factor: 3.313